Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 17/20 | 0.43 |
| ▸ | IKBKB | O14920 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | GRK5 | P34947 | 2/20 | 0.36 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15254184 | 0.81 | FYN (0.55) | FYNIKBKB | |
| SCHEMBL19467118 | 0.81 | IKBKB (0.44) | FYNIKBKBCYP3A4CYP2A6CYP2C9 | |
| SCHEMBL19467148 | 0.79 | FYN (0.62) | FYNIKBKB | |
| SCHEMBL15254310 | 0.78 | DYRK1A (0.46) | FYNIKBKBCYP3A4CYP2A6CYP2C9 | |
| SCHEMBL16554474 | 0.78 | DYRK1A (0.48) | FYNIKBKBCYP3A4CYP2A6CYP2C9 | |
| SCHEMBL16554810 | 0.77 | FYN (0.41) | FYNIKBKBCYP3A4CYP2A6CYP2C9 | |
| SCHEMBL16010271 | 0.76 | PIK3CD (0.52) | FYNGRK5 | |
| SCHEMBL4692424 | 0.75 | FYN (0.64) | FYNIKBKB | |
| SCHEMBL15254599 | 0.74 | MKNK1 (0.57) | FYNIKBKB | |
| SCHEMBL15254545 | 0.74 | IKBKB (0.53) | FYNIKBKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4159741-A1 | METHOD FOR PRODUCING A CHIMERIC POLYNUCLEOTIDE ENCODING A POLYPEPTIDE HAVING A TRIAZOLE-CONTAINING INTERNUCLEOTIDE LINKAGE | ModernaTX, Inc. (US) | 2023-04-05 | — | — | EP | disclosed |
| EP-3169335-A2 | CIRCULAR POLYNUCLEOTIDES | Moderna Therapeutics, Inc. (US) | 2017-05-24 | — | — | EP | disclosed |
| EP-3169693-A1 | CHIMERIC POLYNUCLEOTIDES | Moderna Therapeutics, Inc. (US) | 2017-05-24 | — | — | EP | disclosed |
| EP-3041473-A1 | IMIDAZO[1,2-b]PYRIDAZINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | Lexicon Pharmaceuticals, Inc. (US) | 2016-07-13 | — | — | EP | disclosed |
| EP-3041934-A1 | CHIMERIC POLYNUCLEOTIDES | Moderna Therapeutics, Inc. (US) | 2016-07-13 | — | — | EP | disclosed |
| WO-2016011226-A1 | CHIMERIC POLYNUCLEOTIDES | MODERNA THERAPEUTICS, INC. (US) | 2016-01-21 | — | — | WO | disclosed |
| WO-2016011222-A2 | CIRCULAR POLYNUCLEOTIDES | MODERNA THERAPEUTICS, INC. (US) | 2016-01-21 | — | — | WO | disclosed |
| US-20150183791-A1 | IMIDAZO[1,2-b]PYRIDAZINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. | 2015-07-02 | — | — | US | disclosed |
| US-20150183791-A1 | IMIDAZO[1,2-b]PYRIDAZINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. | 2015-07-02 | — | — | US | disclosed |
| US-20150183791-A1 | IMIDAZO[1,2-b]PYRIDAZINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. | 2015-07-02 | — | — | US | disclosed |
| WO-2015034928-A1 | CHIMERIC POLYNUCLEOTIDES | MODERNA THERAPEUTICS, INC. (US) | 2015-03-12 | — | — | WO | disclosed |
| WO-2015035167-A1 | IMIDAZO[1,2-b]PYRIDAZINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. (US) | 2015-03-12 | — | — | WO | disclosed |
| WO-2015035167-A1 | IMIDAZO[1,2-b]PYRIDAZINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. (US) | 2015-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150183791-A1 | IMIDAZO[1,2-b]PYRIDAZINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | IRAK2, IRAK1, GRB2 | FYN 712/4885IKBKB 381/4885CYP3A4 4733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.